2Secchi LA, Grady EF, Griffin CA, et al. Distribution of angiotensin Ⅱ receptor subtypes in rat and human kidney, Am J Physiol, 1992,262(2 Pt 2) :236 - 240.
4Schmermund A, Lerman LO,Ritman ET, et al. Cardiac production of angiotensin Ⅱ and its pharmacologic inhibition: effects on the coronary circulation. Mayo Clin Proc, 1999,74 ( 5 ) : 503 - 513.
3Schmermand A, lerman LO, Ritman ET et al. Mayo olin Proc,1999;74:503-13
41999 world Health Organizition-International Society of Hypertension Guidelines for the Management of Hypertension Guidelines Subcommittee. J Hypertens, 1999; 17:151～83
5Faulhaber HD, Mann JF, Stein G et al. Effect of valsartan on renal function in patients with hypertension and stable renal insufficiency.Curr Ther Res, 1999;60:170～83
6Plum J, Bünten B, Nemeth R et al. Effects of the angiotensin Ⅱ antagonist Valsartan on blood pressure, proteinuria and renal hemodynamics in patients with chronic renal failure and hypertension. J Am Soc Nephrol, 1998;9:2223～34
7Markham A, Karen LG. Valsartan a review of its pharmacology and therapeutic use in essential hypertension. Durgs, 1997; 54:299～311
8Waldmeier F, Flesch G, Müller P et al. Pharmacokinetics, disposition and biotransformation of [ 14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose. Xenobiotica, 1997; 27: 59～71
9Bauer JH, Reams GP. The angiotensin Ⅱ type 1 receptor antagonists. A new class of anti-hypertensive drugs. Arch Intern Med,1995;155:1361 ～8
10McIntyre M, Caffe SE, Michalak RA et al. Losartan, an orally active angiotensin(AT1 ) receptor antagonist: a review of its efficiency and safety in essential hypertension. Pharmacol Ther, 1997:282～94
